Replies to post #100620 on Amarantus Bioscience Holdings Inc (AMBS)

[breezy1]

The ADHD market is valued at over $3.5 billion dollars, with approximately 35 million prescriptions written annually.

Read more: Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD - FierceBiotech http://www.fiercebiotech.com/press-releases/amarantus-announces-positive-phase-2a-data-eltoprazine-adult-adhd#ixzz30nR29YnN
Subscribe at FierceBiotech


The Company has licensed Eltoprazine a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard").

Read more: Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD - FierceBiotech http://www.fiercebiotech.com/press-releases/amarantus-announces-positive-phase-2a-data-eltoprazine-adult-adhd#ixzz30nRFgY8z
Subscribe at FierceBiotech